Similar articles for PMID: 21989937

Year	Number of Results
1983	1
1995	1
1996	1
1998	2
1999	3
2000	3
2001	3
2002	2
2003	4
2004	2
2005	2
2006	5
2007	4
2008	5
2009	3
2010	6
2011	5
2012	6
2013	7
2014	10
2015	9
2016	4
2017	1
2018	5
2019	2
2020	10
2021	2
2022	5
2023	1
2024	1

1

Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin.

Tamamis P, Pierou P, Mytidou C, Floudas CA, Morikis D, Archontis G. Tamamis P, et al. Proteins. 2011 Nov;79(11):3166-79. doi: 10.1002/prot.23149. Epub 2011 Aug 30. Proteins. 2011. PMID: 21989937 Free PMC article.

2

Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations.

Tamamis P, Morikis D, Floudas CA, Archontis G. Tamamis P, et al. Proteins. 2010 Sep;78(12):2655-67. doi: 10.1002/prot.22780. Proteins. 2010. PMID: 20589629 Free PMC article.

3

Computational analysis of complement inhibitor compstatin using molecular dynamics.

Devaurs D, Antunes DA, Kavraki LE. Devaurs D, et al. J Mol Model. 2020 Aug 12;26(9):231. doi: 10.1007/s00894-020-04472-8. J Mol Model. 2020. PMID: 32789582 Free PMC article.

4

A new generation of potent complement inhibitors of the Compstatin family.

López de Victoria A, Gorham RD Jr, Bellows-Peterson ML, Ling J, Lo DD, Floudas CA, Morikis D. López de Victoria A, et al. Chem Biol Drug Des. 2011 Jun;77(6):431-40. doi: 10.1111/j.1747-0285.2011.01111.x. Epub 2011 Apr 26. Chem Biol Drug Des. 2011. PMID: 21352502 Free PMC article.

5

Molecular dynamics in drug design: new generations of compstatin analogs.

Tamamis P, López de Victoria A, Gorham RD Jr, Bellows-Peterson ML, Pierou P, Floudas CA, Morikis D, Archontis G. Tamamis P, et al. Chem Biol Drug Des. 2012 May;79(5):703-18. doi: 10.1111/j.1747-0285.2012.01324.x. Epub 2012 Feb 9. Chem Biol Drug Des. 2012. PMID: 22233517 Free PMC article.

6

Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.

Soulika AM, Holland MC, Sfyroera G, Sahu A, Lambris JD. Soulika AM, et al. Mol Immunol. 2006 May;43(12):2023-9. doi: 10.1016/j.molimm.2005.12.002. Epub 2006 Feb 10. Mol Immunol. 2006. PMID: 16472861

7

C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles.

Furlong ST, Dutta AS, Coath MM, Gormley JJ, Hubbs SJ, Lloyd D, Mauger RC, Strimpler AM, Sylvester MA, Scott CW, Edwards PD. Furlong ST, et al. Immunopharmacology. 2000 Jul 20;48(2):199-212. doi: 10.1016/s0162-3109(00)00205-8. Immunopharmacology. 2000. PMID: 10936517

8

Compstatin: a complement inhibitor on its way to clinical application.

Ricklin D, Lambris JD. Ricklin D, et al. Adv Exp Med Biol. 2008;632:273-92. doi: 10.1007/978-0-387-78952-1_20. Adv Exp Med Biol. 2008. PMID: 19025129 Free PMC article. Review.

9

Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition.

Janssen BJ, Halff EF, Lambris JD, Gros P. Janssen BJ, et al. J Biol Chem. 2007 Oct 5;282(40):29241-7. doi: 10.1074/jbc.M704587200. Epub 2007 Aug 6. J Biol Chem. 2007. PMID: 17684013 Free article.

10

Studies of structure-activity relations of complement inhibitor compstatin.

Soulika AM, Morikis D, Sarrias MR, Roy M, Spruce LA, Sahu A, Lambris JD. Soulika AM, et al. J Immunol. 2003 Aug 15;171(4):1881-90. doi: 10.4049/jimmunol.171.4.1881. J Immunol. 2003. PMID: 12902490

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year